Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : rQNestin34.5
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Candel Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Details : This acquisition solidifies Candel’s viral therapy leadership position and supports further development of Candel’s rQNestin34.5, currently in a Phase 1 study for recurrent malignant gliomas.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Undisclosed
August 01, 2020
Lead Product(s) : rQNestin34.5
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Candel Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition